02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
13:08 , Dec 4, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers Analysis of the copy numbers of mutant and wild-type alleles of oncogenes could help predict response to cancer therapies targeting those oncogenes. The method involves: performing genome-wide, allele-specific copy number...
20:04 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting phosphorylation of BRAF at S729 could enhance the efficacy of BRAF inhibitors for BRAF V600E-mutant melanoma. In two human BRAF V600E-mutant melanoma cell lines treated with...
19:45 , Nov 6, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays; gene profiling; tissue markers Gene profiling coupled with cell-based assays of patient samples could help predict drug responses in AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of...
22:59 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest the generic antibiotic nifuroxazide could help treat melanoma. In two human metastatic melanoma cell lines, nifuroxazide plus the BRAF inhibitor Zelboraf vemurafenib and the MEK inhibitor Mekinist...
00:07 , Sep 28, 2018 |  BC Innovations  |  Tools & Techniques

Deconstructing tox in immuno-oncology

The best route to improving preclinical toxicity in immunotherapies could lie in reverse translation, feeding clinical data back into the preclinical space to inform model development, rather than trying to guess a priori what the...
17:31 , Sep 26, 2018 |  BC Innovations  |  Distillery Techniques

Assay and screens; other

TECHNOLOGY: Cell-free assays; computational models A computational model based on mutations in plasma cell-free DNA (cfDNA) could help predict the time to progression in mCRC patients treated with anti-EGFR therapies. Construction of the model involves...
01:21 , Sep 21, 2018 |  BC Innovations  |  Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
18:48 , Sep 7, 2018 |  BC Week In Review  |  Company News

Beigene, Springworks testing combo for solid tumors

SpringWorks Therapeutics LLC (New York, N.Y.) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) partnered to test a combination therapy in a Phase Ib trial to treat advanced solid tumors. The trial, which is slated to start in...
10:02 , Sep 6, 2018 |  BC Extra  |  Company News

BeiGene, SpringWorks testing combo for solid tumors

SpringWorks Therapeutics LLC (New York, N.Y.) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) partnered to test a combination therapy in a Phase Ib trial to treat advanced solid tumors. The trial, which is slated to start in...